Biopharmaceutical companies pursuing oncology and rare disease programs are shifting more early-stage research to external partners because these areas require complex disease models, specialized animal handling, and study designs tailored to small, highly targeted pipelines. In the in vivo CRO market, this outsourcing behavior is increasing demand for providers that can run efficacy, pharmacology, and toxicology studies with the technical depth needed for tumor biology, immuno-oncology, and orphan indications. Sponsors are using CROs to move candidates through preclinical decision points without building costly internal infrastructure for niche models that may only be needed for selected programs, which is strengthening market development for specialized in vivo service platforms.

Growing cell and gene therapy pipelines accelerating investments in specialized in vivo testing capabilities

Cell and gene therapy development is pushing the in vivo CRO market toward more advanced testing capabilities because these products require evaluation methods that differ from conventional small molecules, including biodistribution, persistence, immunogenicity, and vector-related safety assessment. CROs are responding by investing in specialized models, analytical workflows, and technical staff able to support complex preclinical packages for viral vectors, engineered cells, and gene-edited therapies. This transition is influencing market adoption in favor of providers that can integrate in vivo execution with therapy-specific interpretation, as sponsors increasingly select partners based on their ability to handle novel mechanisms and generate data suited to translational development decisions.

Rising regulatory complexity in biologics development increasing pharmaceutical reliance on CRO partnerships

As biologics programs face more demanding preclinical evidence requirements, pharmaceutical and biotechnology companies are relying more heavily on external partners that understand study design expectations, documentation standards, and species-selection challenges tied to large molecules and other advanced modalities. The in vivo CRO market benefits from this trend because sponsors are not only outsourcing study execution but also depending on CROs to help structure development plans that reduce regulatory risk before clinical entry. Demand is concentrating around organizations with established quality systems, biologics-specific in vivo expertise, and the operational discipline to produce data packages that align with evolving review standards, contributing to market size growth through deeper and longer-term client engagement.